

Sub B1
cont.

~~acid α -glucosidase at a regular interval, wherein the human acid α -glucosidase was produced in Chinese hamster ovary cell cultures.~~

- A2*
8. (Amended) The method of Claim 1, wherein the human acid α -glucosidase is recombinant human acid α -glucosidase that has been produced in chinese hamster ovary cell cultures.
9. (Amended) The method of Claim 1, wherein the human acid α -glucosidase is a precursor of recombinant human acid α -glucosidase that has been produced in chinese hamster ovary cell cultures.
- any body*
- Sub B3*
21. (Amended) A method of treating cardiomyopathy associated with glycogen storage disease type II in an individual, comprising administering to the individual a therapeutically effective amount of human acid α -glucosidase at a regular interval, wherein the human acid α -glucosidase was produced in chinese hamster ovary cell culture.
- A3*
22. (Amended) A pharmaceutical composition comprising human acid α -glucosidase, wherein the human acid α -glucosidase was produced in chinese hamster ovary cell culture, in a container with a label containing instructions for administration of the composition for treatment of glycogen storage disease type II.

REMARKS

Claim 10 has been canceled. Claims 1, 8, 9, 21 and 22 have been amended to specify that the human acid α -glucosidase (hGAA) was produced in Chinese hamster ovary (CHO) cell culture. Support for this amendment is found throughout the Specification, including, for example, at page 6, lines 3-13, and in canceled Claim 10. No new matter has been added.

Claims 1-9 and 11-22 are pending.